Citations

Clear

511 citation(s) found for "Seth, N".

Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
Jagtap, Kshitij , Naveen, R, Day, Jessica , Sen, Parikshit , Vaidya, Binit , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Agarwal, Vishwesh , Saha, Sreoshy , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Makol, Ashima , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Group, COVAD Study, Kardeş, Sinan , Schreiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit , Atzeni, Fabiola , Bocci, Elena Bartoloni, Sebastiani, Marco, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Alluno, Alessia, Ioannone, Florenzo, Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, Miguel , Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Ravichandran, Naveen , Gupta, Latika , Naveen, R , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Joshi, Mrudula , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vishwesh , Day, Jessica , Tan, Ai Lyn , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Chen, Yi‐Ming , Chatterjee, Tulika , Distler, Oliver , Group, COVAD Study, Griger, Zoltán , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco, Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Giollo, Alessandro , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Gonzalez, Raquel Aranega, Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Maurier, F. , Campagne, Julien , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , Olaosebikan, Hakeem , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Aggarwal, Rohit

Mayo Clinic

Rheumatology | March 24, 2023 | Volume: 62 | Issue: 12 | Pages: 3838-3848

10.1093/rheumatology/kead144 | PMID 36961331 Get It

Abstract Objective Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys. Methods The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs. Results Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a–d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P < 0.001) and autoimmune disease multimorbidity (AIDm) (P < 0.001). In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective. A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P < 0.001). Conclusion Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
The Fate of Residual Fragments After Percutaneous Nephrolithotomy: Results from the Endourologic Disease Group for Excellence Research Consortium
Wong, Victor K. , Que, Jessica, Kong, Emily, Abedi, Garen , Nimmagadda, Naren , Emmott, Anthony S. , Paterson, Ryan F. , Lange, Dirk , Lundeen, Colin , Nevo, Amihay , Shee, Kevin , Pais, Vernon M., Sur, Roger L. , Bechis, Seth K. , Miller, Nicole L. , Hsi, Ryan S. , Knudsen, Bodo E. , Sourial, Michael , Humphreys, Mitchell R. , Stern, Karen , Eisner, Brian H. , Hsi, Ryan , Knudsen, Bodo , Chew, Ben H , Stern, Karen L , Miller, Nicole L , Kong, Emily K., Moore, Jonathan, Chew, Ben H.

Mayo Clinic

Journal of Endourology | March 24, 2023 | Volume: 37 | Issue: 6 | Pages: 617-622

10.1089/end.2022.0561 | PMID 36960704 Get It

Background: Residual fragments (RFs) after percutaneous nephrolithotomy (PCNL) have a significant impact on patients' quality of life and clinical course. There is a paucity of studies that evaluate the natural history of RFs after PCNL. The objective of this study is to compare rates of reintervention, complications, stone growth, and passage in patients with RFs >4, ≤4, and ≤2 mm after PCNL. Methods: Sites from the Endourologic Disease Group for Excellence (EDGE) research consortium examined data of PCNL patients from 2015 to 2019 with at least 1-year follow-up. RF passage, regrowth, reintervention, and complications were recorded and RFs were stratified into >4 and ≤4 mm groups, as well as >2 and ≤2 mm groups. Potential predictors for stone-related events after PCNL were determined using multivariable logistic regression analysis. It was hypothesized that larger RF thresholds would result in lower passage rates, faster regrowth, and greater clinically significant events (complications and reinterventions) than smaller RF thresholds. Results: A total of 439 patients with RFs >1 mm on CT postoperative day 1 were included in this study. For RFs >4 mm, rates of reintervention were found to be significantly higher and Kaplan–Meier curve analysis showed significantly higher rates of stone-related events. Passage and RF regrowth were not found to be significantly different compared with RFs ≤4 mm. However, RFs ≤2 mm had significantly higher rates of passage, and significantly lower rates of fragment regrowth (>1 mm), complications, and reintervention compared with RFs >2 mm. On multivariable analysis, older age, body mass index, and RF size were found to be predictive of stone-related events. Conclusions: With the largest cohort to date, this study by the EDGE research consortium further confirms that clinically insignificant residual fragment is problematic for patients after PCNL, particularly in older more obese patients with larger RFs. Our study underscores the importance of complete stone clearance post-PCNL and challenges the use of Clinically insignificant residual fragment (CIFR).
Primary Pancreatic Undifferentiated Pleomorphic Sarcoma
Patel, M. , Agrawal, Upasana, Kendziora, Ryan W., Vege, Santhi Swaroop , Sweetser, Seth , Patel, Mehrie Harshad , Guerrero Vinsard, Daniela , Swaroop Vege, Santhi, Vinsard, Daniela Guerrero , Siontis, Brittany L.

Mayo Clinic

ACG Case Reports Journal | March 22, 2023 | Volume: 10 | Issue: 3 | Pages: e01011

10.14309/crj.0000000000001011 | PMID 36968124 Get It

ABSTRACT Primary pancreatic sarcomas are rare malignancies with an incidence of 0.1%. This case report is of a 48-year-old man who presented with this condition. The patient's treatment plan consisted of distal pancreatectomy and splenectomy with intraoperative immunohistochemistry and adjuvant chemotherapy. To correctly identify and treat undifferentiated pleomorphic sarcoma, a stepwise strategy involving cross-sectional imaging and extensive histopathology analysis is necessary.
Abstract P2-11-06: Plasma assay of methylated DNA markers (MDM) detects patients with metastatic breast cancer (MBC) compared to healthy controls and treated breast cancer patients with no evidence of disease
Taylor, William R. , O’Connell, Maria C., Robran, Mariah J., Devens, Mary E., Gonser, Anna M. , Burger, Kelli N. , Kaiser, Michael , Allawi, Hatim T. , Ruddy, Kathryn J. , Giridhar, Karthik V. , Couch, Fergus J. , Sinnwell, Jason P. , Slettedahl, Seth W. , Mahoney, Douglas W. , Foote, Patrick H. , O'Connell, Maria C., Larson, Nicole, Doering, Karen A. , Kaiser, Michael, Olson, Janet E. , Kisiel, John B.

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: P2-11-06-P2-11-06

10.1158/1538-7445.sabcs22-p2-11-06 Get It

Abstract Objective: Aberrantly methylated DNA may be used to detect minimal residual disease or early recurrence in breast cancer. As a 1st step, we aimed to develop an MDM panel to delineate between healthy women, stage I-III breast cancer in remission with no evidence of disease (NED), and metastatic breast cancer (MBC). Methods: We prospectively enrolled patients into 3 groups: healthy controls (adult females with a normal mammogram in past 12 months with no history of breast cancer), NED [stage I-III breast cancer with no clinical evidence of recurrence 6 months - 3 years post-treatment (adjuvant endocrine therapy allowed)], and MBC (collected either at initial diagnosis of untreated metastatic disease or radiographic progression). DNA was extracted from 6 mL of plasma derived from blood collected in LBgard tubes (Exact Sciences Corp., San Diego CA), and was bisulfite-treated and assayed by target enrichment long-probe quantitative amplified signal (TELQASTM) method for a panel of 15 previously identified MDMs [Table], normalized by the control gene, B3GALT6. Areas under the receiver operating characteristic curve (AUC) were calculated for each MDM to assess discrimination of MBC from other groups. With 60 patients per group, we had greater than 80% power to detect a difference of 0.20 from the null AUC of 0.7. Results: We tested samples from 60 MBC (10 untreated, 50 recurrent), 60 NED, and 60 healthy women. The median age was 63 (IQR, 55-72) and was not different between groups. The NED group was all hormone-receptor (HR) positive, with 47 (78%) being human epidermal growth factor receptor 2 negative (HER2-) and 13 (22%) HER2+; 48 (80%) were stage I and 9 (15%) were N+. The MBC group had 35 (58%) patients with HR+/HER2- tumors, 11 (18%) HR+/HER2+, and 6 (10%) HR-/HER2-, 4 (7%) HR-/HER2+, with 4 (7%) unknown. Of the 41 MBC whose original stage and nodal status were known 9 (22%) were stage I and 22 (54%) were N+. The markers were able to discriminate between MBC and NED patient samples with AUCs from 0.97 to 0.72. AUCs for 10/15 MDMs (ITPRIPL1, EMX1, C17orf64, OSR2, TRIM67, CHST2, IFFO1, TRH, FAM59B, and MPZ) were >0.90. No difference in MDMs was observed between the healthy and NED groups. Conclusions: MDMs, assayed from plasma, appear highly discriminant for metastatic breast cancer cases in comparison to control patients with NED or healthy controls. Further clinical validation of this MDM panel in a larger cohort is warranted. Table 1. Plasma MDM discrimination of metastatic breast cancer (MBC) from healthy controls and previously treated breast cancer patients with no evidence of disease (NED) Citation Format: Karthik V. Giridhar, Fergus J. Couch, Jason P. Sinnwell, Seth W. Slettedahl, William R. Taylor, Douglas W. Mahoney, Patrick H. Foote, Maria C. O’Connell, Mariah J. Robran, Mary E. Devens, Anna M. Gonser, Nicole Larson, Karen A. Doering, Kelli N. Burger, Michael Kaiser, Hatim Allawi, Kathryn Ruddy, Janet Olson, John B. Kisiel. Plasma assay of methylated DNA markers (MDM) detects patients with metastatic breast cancer (MBC) compared to healthy controls and treated breast cancer patients with no evidence of disease [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-11-06.
The certified child life specialist: A novel resource in the pediatric primary care clinic for managing children's pain during routine immunizations
Gregory, Seth W. , Aul, Andrea J., Lodermeier, Tara M., Rodemeyer, Jennifer L., Weaver, Amy L. , Lynch, Brian , Aul, Andrea J.

Mayo Clinic

Paediatric and Neonatal Pain | March 1, 2023 | Volume: 5 | Issue: 3 | Pages: 66-75

10.1002/pne2.12101 | PMID 37744282 Get It

Abstract This study evaluated the effect of the Certified Child Life Specialist (CCLS) on pediatric pain and pain management during routine immunization administration in the pediatric primary care clinic. Children 4–12 years of age ( n = 125) presenting for a well child physical examination at a rural primary care clinic were selected to receive standard nursing care or standard nursing care plus CCLS support during routine immunization administration. Patient reported pain was measured using the Faces Pain Scale‐Revised (FPS‐R), and patient behavioral responses were measured during immunization administration using the Children's Emotional Manifestation Scale (CEMS). The performance of psychosocial interventions and administration of topical pain‐relieving interventions were measured between both groups. CCLS support was associated with fewer negative emotional behaviors during immunization administration among 7‐ to 12‐year‐old children and a significantly higher provision of psychosocial interventions and topical pain‐relieving interventions among all ages. This study demonstrates that the presence of a CCLS can increase the provision of psychosocial and pain‐relieving interventions and reduce distress during immunization administration in a busy pediatric primary care clinic.
The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
Pant, Kishor , Richard, Seth , Peixoto, Estanislao , Yin, Jun , Seelig, Davis , Carotenuto, Pietro , Salati, Massimiliano, Franco, Brunella , Roberts, Lewis R. , Gradilone, Sergio A. , Roberts, Lewis R , Gradilone, Sergio A , Salati, Massimiliano

Mayo Clinic

Cells | March 1, 2023 | Volume: 12 | Issue: 5 | Pages: 775

10.3390/cells12050775 | PMID 36899911 Get It

It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells. The major enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathways, nicotinamide phosphoribosyltransferase (NAMPT), is essential for cancer cell survival and metastasis. Previous research has shown that the targeted NAMPT inhibitor FK866 reduces cancer cell viability and triggers cancer cell death; however, whether FK866 affects CCA cell survival has not been addressed before. We show herein that NAMPT is expressed in CCA cells, and FK866 suppresses the capacity of CCA cells to grow in a dose-dependent manner. Furthermore, by preventing NAMPT activity, FK866 significantly reduced the amount of NAD+ and adenosine 5′-triphosphate (ATP) in HuCCT1, KMCH, and EGI cells. The present study’s findings further show that FK866 causes changes in mitochondrial metabolism in CCA cells. Additionally, FK866 enhances the anticancer effects of cisplatin in vitro. Taken together, the results of the current study suggest that the NAMPT/NAD+ pathway may be a possible therapeutic target for CCA, and FK866 may be a useful medication targeting CCA in combination with cisplatin.
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Sen, Parikshit , Naveen, R, Houshmand, Nazanin , Moghadam‐Kia, Siamak , Joshi, Mrudula , Saha, Sreoshy , Jagtap, Kshitij , Agarwal, Vishwesh , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chatterjee, Tulika , Day, Jessica , Chinoy, Hector , Group, COVAD Study, Kardeş, Sinan , Lini, Daniele , Screiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pande, Arun K. , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Fusaro, Enrico , Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Venerito, Vincenzo , Grignaschi, Silvia, Giollo, Alessandro, Alluno, Alessia, Ioannone, Florenzo, Loarce‐Martos, Jesus , Prieto‐González, Sergio , González, Raquel , Yoshida, Akira , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Emorinken, Airenakho , Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Sáenz, Ricardo A., Escalante, Miguel , Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Gupta, Latika, Ravichandran, Naveen , Giollo, Alessandro , Grignaschi, Silvia , Gupta, Latika , Naveen, R , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Day, Jessica , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , Yoshida, Akira , De Angelis, Rossella , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Makol, Ashima , Chen, Yi‐Ming , Distler, Oliver , Group, COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Fonseca, João Eurico , Zimba, Olena , Ugarte‐Gil, Manuel F. , Salinas, Rodrigo Nicolás Garcia , Saenz, Ricardo, Aggarwal, Rohit

Mayo Clinic

Rheumatology | February 3, 2023 | Volume: 62 | Issue: 10 | Pages: 3291-3301

10.1093/rheumatology/kead057 | PMID 36734536 Get It

Abstract Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs – OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs – OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7–10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8–0.97)]. Conclusion Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5‐Year Update
Tierney, William S. , Huang, Li‐Ching , Chen, Sheau‐Chiann , Berry, Lynn D., Anderson, Catherine , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, Catherine Gaelyn, Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Daele, Douglas J. Van , Chen, Sheau-Chiann , Cohen, Seth M , Hoffman, Henry T , Weissbrod, Philip A , Amin, Milan R , Bock, Jonathan M. , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Netterville, James L. , Ongkasuwan, Julina , Rohde, Sarah L. , Rohlfing, Matthew L. , Weinberger, Paul , Gelbard, Alexander

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 19, 2023 | Volume: 168 | Issue: 6 | Pages: 1570-1575

10.1002/ohn.190 | PMID 36939627 Get It

Abstract The North American Airway Collaborative (NoAAC) previously published a 3‐year multi‐institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re‐enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision‐making. Level of evidence: 2—prospective cohort study.
A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities
Beatty, Alexis L. , Beckie, Theresa M. , Dodson, John A. , Goldstein, Carly M. , Hughes, Joel W. , Kraus, William E. , Olson, Thomas P. , Pack, Quinn R. , Stolp, Haley , Franklin, Barry A. , Martin, Seth S , Stolp, Haley , Wu, Wen-Chih , Beatty, Alexis L , Martin, Seth S. , Thomas, Randal J. , Wu, Wen‐Chih

Mayo Clinic

Circulation | January 17, 2023 | Volume: 147 | Issue: 3 | Pages: 254-266

10.1161/circulationaha.122.061046 | PMID 36649394 Get It

Cardiac rehabilitation (CR) is a guideline-recommended, multidisciplinary program of exercise training, risk factor management, and psychosocial counseling for people with cardiovascular disease (CVD) that is beneficial but underused and with substantial disparities in referral, access, and participation. The emergence of new virtual and remote delivery models has the potential to improve access to and participation in CR and ultimately improve outcomes for people with CVD. Although data suggest that new delivery models for CR have safety and efficacy similar to traditional in-person CR, questions remain regarding which participants are most likely to benefit from these models, how and where such programs should be delivered, and their effect on outcomes in diverse populations. In this review, we describe important gaps in evidence, identify relevant research questions, and propose strategies for addressing them. We highlight 4 research priorities: (1) including diverse populations in all CR research; (2) leveraging implementation methodologies to enhance equitable delivery of CR; (3) clarifying which populations are most likely to benefit from virtual and remote CR; and (4) comparing traditional in-person CR with virtual and remote CR in diverse populations using multicenter studies of important clinical, psychosocial, and cost-effectiveness outcomes that are relevant to patients, caregivers, providers, health systems, and payors. By framing these important questions, we hope to advance toward a goal of delivering high-quality CR to as many people as possible to improve outcomes in those with CVD.
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study
Hess, Brian , Giri, Anshu , Park, Yeonhee , Patel, Krina K. , Link, Brian K. , Nowakowski, Grzegorz S. , Maliske, Seth , Chávez, Julio C. , Hill, Brian T. , Garcia, Alex, Maddocks, Kami J. , Wagner‐Johnston, Nina D. , Messmer, Marcus R., Watkins, Marcus P. , Alderuccio, Juan Pablo , Lossos, Izidore S., Nathan, Sunita , Portell, Craig A. , Ayers, Emily C. , Fortin, Sonia, Chavez, Julio C , Watkins, Marcus , Alderuccio, Juan Pablo , De La Fuente, Macarena , Landsburg, Daniel J , Castillo, Jorge J , Link, Brian K , Portell, Craig A , Fortin, Sonia, Saeed, Hayder , Hanel, Walter G. , Messmer, Marcus , Kahl, Brad S. , Lossos, Izidore S. , Orellana‐Noia, Victor M. , Landsburg, Daniel J. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | January 2, 2023 | Volume: 98 | Issue: 2 | Pages: 300-308

10.1002/ajh.26784 | PMID 36588409 Get It

AbstractPlasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high relapse rates and a poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, a specific review of limited stage (LS) PBL patients is not available to evaluate outcomes and justify treatment recommendations. We performed a retrospective review of LS PBL cases to provide insight into this rare disease. Our cohort consisted of 80 stage I or II PBL patients from 13 US academic centers. With a median follow up of 34 months (1–196), the 3‐year progression‐free survival (PFS) and overall survival (OS) of the entire cohort were 72% (95% CI 62, 83) and 79% (95% CI 70, 89), respectively. The 3‐year PFS and OS of patients treated with frontline chemotherapy alone was 65% (95% CI 50, 84) and 71% (95% CI 56, 89), respectively, compared to 85% (95% CI 72, 100) and 96% (95% CI 89, 100), respectively, in patients treated with combined frontline chemotherapy with radiation consolidation. Our data demonstrate favorable outcomes in LS PBL with no improvements in outcome from aggressive frontline treatment including Hyper‐CVAD or auto‐SCT consolidation. Multivariate regression analysis (MRA) demonstrated improved PFS for patients receiving EPOCH based frontline therapy versus CHOP (HR: 0.23; p = 0.029). Frontline chemotherapy followed by radiation consolidation versus chemotherapy alone appeared to be associated with improved relapse and survival outcomes but did not show statistical significance in MRA.